Psychopharmacology in supportive care of cancer: A review for the clinician IV. Other psychotropic agents

Supportive Care in Cancer

Volumn 9, Issue 4, 2001, Pages 213-222

  Buclin, T ^a   Mazzocato, C ^a   Berney, A ^a   Stiefel, F ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Palliative care; Psychotropic drugs; Supportive care

Indexed keywords

AMPHETAMINE DERIVATIVE; ANALGESIC AGENT; ANESTHETIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ANXIOLYTIC AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BRONCHODILATING AGENT; BUSPIRONE; CAFFEINE; CANNABIS DERIVATIVE; CENTRAL STIMULANT AGENT; CHLORAL HYDRATE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DEXTROMETHORPHAN; HYPNOTIC AGENT; KETAMINE; MELATONIN; METHYLPHENIDATE; NARCOTIC AGENT; NEUROLEPTIC AGENT; PROPOFOL; SEDATIVE AGENT; UNINDEXED DRUG; ZOLPIDEM; ZOPICLONE;

ANESTHESIA; ARTICLE; CANCER; CLINICAL TRIAL; DOSE RESPONSE; DRUG CHOICE; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; HUMAN; INSOMNIA; PALLIATIVE THERAPY; PATIENT CARE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; SEDATION; SLEEP DISORDER; STEROID THERAPY; TERMINAL CARE; WITHDRAWAL SYNDROME;

ANTI-ANXIETY AGENTS; CENTRAL NERVOUS SYSTEM DEPRESSANTS; CENTRAL NERVOUS SYSTEM STIMULANTS; HUMANS; NEOPLASMS; PAIN; PALLIATIVE CARE; PSYCHOTROPIC DRUGS; SLEEP DISORDERS;

EID: 0034975190     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005200000191     Document Type: Article

References (108)

1. The effects of cannabinoids on the brain
2. Epidemiology of sleep disorders
3. Central nervous system stimulants as symptomatic treatments for AIDS-related neuropsychiatric impairment
4. Randomised controlled trials in single patients
5. Buspirone: Future directions
6. Buspirone effect on breathlessness and exercise performance in patients with chronic obstructive pulmonary disease
7. A comparison of chlormethiazole and thioridazine in agitated confusional states of the elderly
8. The beneficial and adverse effects of hypnotics
9. Treatment outcome in a multidisciplinary cancer pain clinic
10. Antidepressant effects of ketamine in depressed patients
11. Drug interactions in palliative care
12. Psychopharmacology in supportive care of cancer: A review for the clinician. III. Antidepressants
13. The use of methylphenidate for cognitive decline associated with HIV disease
14. The uses of psychotropics in symptom management in advanced cancer
15. Action of oral methylprednisolone in terminal cancer patients: A prospective randomized double-blind study
16. Double-blind evaluation of mazindol in enhancing the comfort of terminally ill cancer patients
17. The use of methylphenidate in patients with incident cancer pain receiving regular opiates
18. Rapid discontinuation of hypnotics in terminal cancer patients: A prospective study
19. Gabapentin as an adjuvant to opioid analgesia for neuropathic cancer pain
20. Paradoxic excitation with diphenhydramine in an adult
21. The preoperative administration of intravenous dextromethorphan reduces postoperative morphine consumption
22. Effective treatment of severe cancer pain of the head using low-dose ketamine in an opioid-tolerant patient
23. Buspirone for anxiety disorders in patients with severe lung disease
24. Hypnotic effect of chlormethiazole in geriatric patients during long-term treatment
25. Distribution of central omega 1 (benzodiazepine 1: BZD 1) and omega 2 (BZD 2) receptor subtypes in the monkey and human brain: An autoradiographic study with (3H) flunitrazepam and the omega 1 selective ligand (3H) zolpidem
26. Endocannabinoids: Endogenous cannabinoid receptor ligands with neuromodulatory action
27. Comparison of the effects of zolpidem and flunitrazepam on sleep structure and daytime Cognitive functions
28. Examining the debate on the use of medical marijuana
29. Depression in the medically ill elderly: A focus on methylphenidate
30. Clinical experience with oral ketamine
31. Caffeine withdrawal: A parametric analysis of caffeine dosing conditions
32. Effects of methylphenidate in HIV-related depression: A comparative trial with desipramine
33. Low-dose ketamine in the management of opioid nonresponsive terminal cancer pain
34. Dextroamphetamine with morphine for the treatment of post-operative pain
35. Methylphenidate for depression in the elderly, medically ill patient
36. Buspirone, an anxiolytic drug that stimulates respiration
37. A guide to enteral drug administration in palliative care
38. Comparison of oxazepam, flurazepam and chloral hydrate as hypnotic sedatives in geriatric patients
39. Chlormethiazole sedation for critically ill patients in renal failure
40. Sensitivity to triazolam in the elderly
41. Medicinal marijuana: A comprehensive review
42. N of 1 randomised controlled trials of oral ketamine in patients with chronic pain
43. Analgesic effect of the cannabinoid analogue nabilone is not mediated by opioid receptors
44. Psychostimulants in supportive care
45. A survey of psychotropic drug utilization by patients with advanced neoplastic disease
46. Caffeine intake, tolerance, and withdrawal in women: A population-based twin study
47. Methylphenidate hydrochloride as an antidepressant: Controversy, case studies, and review
48. Current concepts: Management of insomnia
49. World Health Organization targets: Insomnia
50. Zolpidem: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential
51. Low doses of epidural ketamine or neostigmine, but not midazolam, improve morphine analgesia in epidural terminal cancer pain therapy
52. Is there a role for melatonin in the treatment of neoplastic cachexia?
53. A survey of antidepressant prescribing in the terminally ill
54. Methylphenidate in terminal depression
55. Psychostimulants for secondary depression in medical illness
56. Psychopharmacology in supportive care of cancer: A review for the clinician. II. Neuroleptics
57. Effects of buspirone on sleep and respiration
58. Propofol in terminal care
59. Ineffectiveness of dextromethorphan in cancer pain
60. Causal or casual? The role of causality assessment in pharmacovigilance
61. Methylphenidate therapy improves cognition, mood, and function of brain tumor patients
62. Interactions between anticonvulsant and psychoactive drugs
63. The management of alcohol withdrawal using chlormethiazole
64. The use of propofol in palliative medicine
65. Abuse of over-the-counter dextromethorphan by teenagers
66. Zopiclone: An update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia
67. Psychostimulants for depression in hospitalized cancer patients
68. A comparative study of lormetazepam and chlormethiazole in elderly inpatients
69. The effects of substituting zopiclone in withdrawal from chronic use of benzodiazepine hypnotics
70. Corticosteroid-induced adverse psychiatric effects: Incidence, diagnosis and management
71. Clinical trials of benzamides in psychiatry
72. Effect of melatonin on jet lag after long haul flights
73. Dextromethorphan-induced mania
74. Antiepileptic drugs in affective illness
75. Dextromethorphan-induced psychosis
76. Pharmacokinetic interactions between antiepileptic drugs
77. Methylphenidate in depressed medically ill patients
78. Clinical efficacy of antihistaminics as analgesics
79. Neuroactive steroids: Mechanisms of action and neuropsychopharmacological perspectives
80. Assessment of drowsiness in epilepsy patients receiving chronic antiepileptic drug therapy
81. NMDA-receptor antagonists in neuropathic pain: Experimental methods to clinical trials
82. Sleep
83. Pharmacological rationale for the clinical use of caffeine
84. Caffeine as an analgesic adjuvant: A review of pharmacology and mechanisms of action
85. Withdrawal syndrome after the double-blind cessation of caffeine consumption
86. Effects of buspirone on anxiety levels and exercise tolerance in patients with chronic airflow obstruction and mild anxiety
87. Clinically significant pharmacokinetic drug interactions with carbamazepine. An update
88. Meta-analysis of the safety and tolerability of two dose regimens of buspirone in patients with persistent anxiety
89. Psychostimulants for hypoactive-hypoalert delirium?
90. Changes in the prescription patterns of psychotropic drugs for cancer patients during a 10-year period
91. Psychopharmacology in supportive care of cancer: A review for the clinician. I. Benzodiazepines
92. Dose dependency of dextromethorphan for cytochrome P450 2D6 phenotyping
93. Dependency of non-benzodiazepine hypnotics. Two case reports
94. Carbamazepine in the prophylaxis of major depression: A 5-year follow-up
95. Comparative study to determine the optimal melatonin dosage form for the alleviation of jet lag
96. Clinically significant pharmacokinetic drug interactions between antiepileptic drugs
97. Palliative therapy in the terminal stage of neurological disease
98. Double-blind, placebo-controlled trial of methylphenidate in older, depressed, medically ill patients
99. Perioperative ingestion of caffeine and postoperative headache
100. Methylphenidate in the treatment of neurobehavioral slowing associated with cancer and cancer treatment
101. A randomized, crossover evaluation of methylphenidate in cancer patients receiving strong narcotic
102. Insomnia in the elderly
103. Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam
104. Analgesic efficacy of paracetamol and its combination with codeine and caffeine in surgical pain - A meta-analysis
105. Sleep-inducing effects of low doses of melatonin ingested in the evening
106. Melatonin: A sleep-promoting hormone
107. Effect of clorazepate on depressed mood in anxious patients